EGFR and breast adenocarcinoma: Dual selective “targeted” delivery of gemcitabine and epirubicin at two different trophic membrane receptors over-expressed (EGFR) or highly over-expressed (HER2/neu) by chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) collectively serve as a prototype strategy for attaining similar properties through the simultaneous application of gemcitabine-(C4-amide)-[anti-EGFR] with epirubicin-(C3-amide)-[anti-HER2/neu] based on the levels of anti-neoplastic cytotoxicity detected at and between the chemotherapeutic equivalent concentrations of 10−9 M and 10−7 M (Figure.